

1 **Nanoarchitectonics of a microsphere-based scaffold for modeling**  
2 **neurodevelopment and neurological disease**

3 Eric S. Sandhurst<sup>a,b</sup>, Sharad V. Jaswandkar<sup>c</sup>, Krishna Kundu<sup>c</sup>, Dinesh R. Katti<sup>c</sup>, Kalpana S. Katti<sup>c</sup>,  
4 Hongli Sun<sup>a,b#</sup>, Daniel Engebretson<sup>a</sup>, Kevin R. Francis<sup>a,b,d,e\*#</sup>

5 <sup>a</sup> Department of Biomedical Engineering, University of South Dakota, Sioux Falls, SD, USA.

6 <sup>b</sup> BioSystems Networks and Translational Research Center, Brookings, SD, USA.

7 <sup>c</sup> Civil, Construction and Environmental Engineering Department, North Dakota State University,  
8 Fargo, ND, USA.

9 <sup>d</sup> Cellular Therapies and Stem Cell Biology Group, Sanford Research, Sioux Falls, SD, USA.

10 <sup>e</sup> Department of Pediatrics, University of South Dakota Sanford School of Medicine, Sioux Falls,  
11 SD, USA.

12

13 \* Corresponding author: K. R. F. ([kevin.francis@sanfordhealth.org](mailto:kevin.francis@sanfordhealth.org)).

14 # Lead Contact: K.R.F. ([kevin.francis@sanfordhealth.org](mailto:kevin.francis@sanfordhealth.org))

15 Keywords: three-dimensional, scaffold, differentiation, neurodevelopment, induced pluripotent  
16 stem cell

17 **Abstract**

18 Three-dimensional (3D) cellular constructs derived from pluripotent stem cells allow the *ex vivo*  
19 study of neurodevelopment and neurological disease within a spatially organized model.  
20 However, the robustness and utility of 3D models is impacted by tissue self-organization, size  
21 limitations, nutrient supply, and heterogeneity. Herein, we have utilized the principles of  
22 nanoarchitectonics to create a multifunctional, polymer/bioceramic composite microsphere  
23 system for stem cell culture and differentiation in a chemically defined microenvironment.  
24 Microspheres could be customized to produce three-dimensional structures of defined size  
25 (ranging from <100 to >350  $\mu$ m) with lower mechanical properties compared to thin-film. Further,  
26 microspheres softened in solution, approaching more tissue-like mechanical properties with time.  
27 Using neural stem cells (NSCs) derived from human induced pluripotent stem cells, microsphere-  
28 cultured NSCs were able to utilize multiple substrates to promote cell adhesion and proliferation.  
29 Prolonged culture of NSC-bound microspheres in differentiating conditions promoted the  
30 formation of both neural and glial cell types from control and patient-derived stem cell models.  
31 Human NSCs and differentiated neurons could also be co-cultured with astrocytes and human  
32 umbilical vein endothelial cells (HUEVCs), demonstrating possible application for tissue-  
33 engineered modeling of development and human disease. We further demonstrate microspheres  
34 allow the loading and sustained release of multiple recombinant proteins to support cellular  
35 maintenance and differentiation. While previous work has principally utilized self-organizing  
36 models or protein-rich hydrogels for 3D neural culture, the three-dimensional matrix presented  
37 here represents a chemically defined and robust alternative for the *in vitro* study of  
38 neurodevelopment and nervous system disorders.

39 Keywords: microsphere, scaffold, three-dimensional, induced pluripotent, iPSC, NSC

40

41


42

43

44

45

46



48 **Introduction**

49 Disorders affecting the nervous system are one of the leading causes of co-morbidity and death  
50 worldwide.<sup>1, 2</sup> Observing and analyzing disease impacts on the nervous system is inherently  
51 challenging within affected individuals. The use of model systems to recapitulate different  
52 structures and functions of the nervous tissue under study provides a mechanism to study  
53 neurological disease. Many of the insights into neuropathological disease have come from  
54 research on post-mortem tissue, traditional two-dimensional (2D) cell culture experiments, and  
55 within animal models such as transgenic mice and rats. Despite the availability of genetic and  
56 technological tools and a robust foundation of neuroscience research, these model systems each  
57 have limitations.<sup>3</sup> Studying the pathogenesis of complex diseases has proven to be particularly  
58 difficult due to a lack of access to healthy and diseased brain tissue, immature and spatially limited  
59 *in vitro* cell culture systems, and animal models that fail to capture the developmental,  
60 architectural, and species-specific aspects of the human brain.<sup>2, 4</sup> Therefore, additional models of  
61 the human nervous system are needed to help overcome some of these limitations.

62 Human induced pluripotent stem cells (iPSCs) have created a fundamental shift in how scientists  
63 study human disease. By establishing a reliable method for generating individual-specific  
64 pluripotent cells, iPSCs represent a robust model system for the study of human disease and may  
65 accelerate progress towards revolutionary treatments.<sup>5</sup> iPSC-derived neural stem cells (NSCs),  
66 therefore, are a useful tool to provide insights into the underlying mechanisms of  
67 neurodevelopment and neurodegenerative diseases. The use of iPSCs has led to new strategies  
68 for therapeutic intervention and increased accuracy for drug discovery.<sup>6-9</sup> Although iPSCs  
69 represent a revolution in studying development and human disease *in vitro*, researchers have  
70 predominantly relied on 2D culture platforms.<sup>10</sup> Since traditional monolayer cultures support only  
71 planar cell-cell interaction, this system poorly simulates the natural three-dimensional (3D)  
72 microenvironment of the body. The natural interaction and communication between the  
73 heterogeneous milieu of cells and the extracellular matrix found within the body is difficult to  
74 replicate in 2D culture.<sup>11</sup> Certain cellular characteristics, including apicobasal polarity and guided  
75 cell migration, cannot be recapitulated in planar culture systems.<sup>12</sup> Spatially complex iPSC models  
76 of neurological disease are thus needed.<sup>13</sup>

77 As recent groundbreaking studies have shown, 3D culture of iPSCs more accurately represents  
78 the spatial arrangement and temporal development of nervous tissue when compared to 2D  
79 models.<sup>3, 14-16</sup> Research conducted with 3D culture models provides new knowledge of areas that  
80 were previously only poorly modeled or inaccessible altogether, such as the cerebral cortex,

81 neocortex, ventral forebrain, ventral telencephalon, cerebellum, midbrain, choroid plexus, and  
82 optic cup.<sup>14-19</sup> Although each 3D protocol has advantages and disadvantages, they all utilize the  
83 capacity of embryonic stem cells or iPSCs to self-organize, self-assemble, and differentiate within  
84 a 3D environment.<sup>2</sup> Known as spheroids, neurospheres, cellular scaffolds or organoids depending  
85 on their complexity and the methods used, these 3D platforms can produce functional, highly-  
86 organized populations of cells.<sup>1, 20, 21</sup> However, 3D models are still limited by experimental  
87 heterogeneity, limited control over tissue organization, inadequate diffusion and heterogeneous  
88 distribution of macromolecules, and endpoint analyses.<sup>17, 22-29</sup>

89 To help overcome the limitations of current 3D models, we have developed a microsphere-based  
90 scaffold with nanoarchitectural features for iPSC-based neural differentiation<sup>30, 31</sup>. Using a  
91 biomaterial-based microenvironment, we have created an alternative to the undefined  
92 components present within other materials-based 3D culture systems. We have defined the  
93 mechanical properties of this scaffold, demonstrated the maintenance and lineage differentiation  
94 of iPSC-derived NSCs cultured on the scaffold, established a protocol for co-culture of multiple  
95 neural and endothelial cell types, and utilized this scaffold for localized cellular delivery of small  
96 molecules. This system represents a novel advancement in 3D culture and provides a  
97 multifunctional platform for disease modeling, drug screening applications, and developmental  
98 studies.

## 99 **Materials and methods**

### 100 *Chemicals and reagents*

101 Poly lactic-co-glycolic acid (PLGA; 50:50, 1.15 dL/g) was purchased from Lactel (Birmingham,  
102 AL). Gelatin Type A, dichloromethane, poly L-ornithine, molecular grade water, bovine serum  
103 albumin (BSA), disodium ethylenediaminetetraacetate (EDTA), and magnesium chloride were  
104 purchased from Sigma Aldrich (St. Louis, MO). Low-attachment 24-well plates, sodium chloride,  
105 sodium bicarbonate, Tris base, Neurobasal media, and epidermal growth factor were purchased  
106 from ThermoFisher Scientific (Carlsbad, CA). B27 supplement with vitamin A, B27 without vitamin  
107 A, Accutase and Glutamax were all purchased from Life Technologies (Carlsbad, CA). Basic  
108 fibroblast growth factor (bFGF) was purchased from Reprocell (Beltsville, MD). Y27632 ROCK  
109 inhibitor was purchased from Reagents Direct (Encinitas, CA). mTeSR1 was purchased from  
110 Stem Cell Technologies (Vancouver, BC). DMEM, DMEM-F12, Penicillin/streptomycin, One Shot  
111 fetal bovine serum, Trypsin-EDTA, and phosphate buffered saline were purchased from Gibco  
112 (Carlsbad, CA). BDNF and GDNF were purchased from Peprotech (Rocky Hill, NJ). Matrigel

113 hESC-Qualified Matrix was purchased from Corning (Glendale, AZ). Laminin was purchased from  
114 Invitrogen (Carlsbad, CA). Hydrochloric acid was purchased from Avantor Performance Materials  
115 (Center Valley, PA). Polyvinyl alcohol was purchased from PolySciences, Inc. (Warrington, PA).  
116 Ethanol, calcium chloride, and sodium phosphate were purchased from Acros Organics (Fair  
117 Lawn, NJ). 96-well ultra-low attachment plates were purchased from Nexcelom Bioscience  
118 (Lawrence, MA).

119 *Preparation of microspheres*

120 A double emulsion procedure was used to prepare porous microspheres. First, 0.5 g of 50:50,  
121 1.15 viscosity PLGA was placed into a glass vial with 15 mL of dichloromethane (DCM). PLGA  
122 was dissolved under constant stirring at 700 rpm at 50 °C. Simultaneously, the primary aqueous  
123 phase was prepared by dissolving 0.4 g of type A porcine gelatin and 5 mg of polyvinyl alcohol  
124 (PVA) in 5 mL of deionized (DI) water in a separate glass vial. A third solution, the secondary  
125 aqueous phase, was prepared by dissolving 200 mg of PVA in 200 mL of DI water and cooled to  
126 4 °C. The dissolved polymer solution was poured into a 25 mL beaker and placed on a hotplate  
127 at 50 °C under the IKA homogenizer (IKA Works, Inc., Wilmington, NC). The aqueous solution  
128 was added manually using a 1000 µL pipette and the two solutions were emulsified for 5 min at  
129 4000 rpm. The primary emulsion was immediately poured into the secondary aqueous phase and  
130 rotated using a magnetic stir plate at 400 rpm for 60 min. After stirring at 400 rpm for 60 min, the  
131 contents of the beaker were poured into 1200 mL of fresh DI water and stirred overnight at 300  
132 rpm to facilitate DCM evaporation. The supernatant was discarded, the microspheres were rinsed  
133 and collected in a 50 mL conical tube, kept at -80 °C for 60 min, and lyophilized for 36 - 48 h.  
134 Following lyophilization, microspheres were treated with an ethanolic sodium hydroxide solution  
135 at a ratio of 20% 1M NaOH and 80% pure ethanol.<sup>32</sup> Microspheres were placed into a 50 mL  
136 conical tube and vortexed for 20 - 30 s. Microspheres were rinsed with DI water, collected in a  
137 nylon cell strainer, kept at -80 °C freezer for 60 min, and lyophilized for 36 - 48 h.

138 *Hydroxyapatite deposition on microspheres*

139 The mineralization process of PLGA microsphere scaffolds was performed as previously  
140 published.<sup>33</sup> Briefly, microspheres were divided into fractions based on diameter (ex: 150 - 300  
141 µm) by filtering them through ATSE metal sieves of decreasing size. Hydroxyapatite (HA) was  
142 formed on the entire exposed surface of the microsphere structure during two phases of  
143 immersion into two solutions known as simulated body fluid (SBF). First, microspheres were  
144 immersed into a phase I nucleation solution (P1). For P1, 19.95 g of NaCl, followed by 0.69 g of

145 CaCl<sub>2</sub>, 0.45 g of NaHPO<sub>4</sub>, 0.88 g of NaHCO<sub>3</sub>, and 0.76 g of MgCl<sub>2</sub> were dissolved in 500 mL DI  
146 water under stirring conditions. 25 mg of microspheres, with a diameter of 150 - 300  $\mu$ m, were  
147 placed into a glass vial and 25 mL of P1 nucleation solution was added to the vial. Each vial was  
148 placed into an orbital shaker, heated to 37 °C, and set for 100 rpm for 12 h. To verify P1 deposition,  
149 a FITC-labeled scrambled peptide (FITC-QEQLERALNSS, Biomatik) was added to the P1 SBF  
150 and imaged by confocal microscopy.<sup>34</sup>

151 After 12 h, microspheres were collected in a nylon cell strainer, kept at -80 °C for 60 min, and  
152 lyophilized for 18 - 24 h. Next, a phase II propagation solution (P2) was created by dissolving  
153 various salts. First, 0.27 g of CaCl<sub>2</sub>, followed by 3.98 g of NaCl, and 0.175 g of NaHPO<sub>4</sub> were  
154 dissolved in 497.5 mL of DI water and 2.5 mL of 10M HCl under stirring conditions. Tris buffer  
155 was added to achieve a pH of 7.4. P1 microspheres were placed in a new glass vial and 25 mL  
156 of P2 propagation solution was added to the vial. Each vial was placed into an orbital shaker,  
157 heated to 35 °C, and set for 100 rpm for 12 h. The microspheres were then collected in a nylon  
158 cell strainer, kept at -80 °C for 20 min, and lyophilized for 18 - 24 h. To verify P2 deposition, BSA  
159 conjugated to AlexaFluor647 (Invitrogen, Carlsbad, CA) was added to P2 SBF and imaged by  
160 confocal microscopy.

161 *Poly-L-ornithine (PLO) and laminin coating of 2D and 3D surfaces*

162 0.2% (v/v) PLO diluted in molecular grade water was added to culture surfaces and allowed to  
163 conjugate for 12 h in a 37 °C incubator. Dishes were rinsed twice with molecular grade water  
164 before a 1% solution (v/v) of natural mouse laminin diluted in PBS was added to each well. Culture  
165 dishes were incubated at 37 °C for 12 h and either used immediately or stored at -20 °C.  
166 Microspheres were immersed in 0.2% (v/v) PLO and placed in an enclosed orbital shaker  
167 maintained at 37 °C and 100 rpm for 12 h. Microspheres were rinsed twice with molecular grade  
168 water and placed into a new glass vial, immersed in a 1% solution of natural mouse laminin and  
169 placed in an enclosed orbital shaker set for 37 °C and 100 rpm for 12 h. PLO+laminin coated  
170 microspheres were kept at 4 °C and used within 12 h.

171 *Ultra-structural characterization of microspheres*

172 A FEI Quanta 450 field-emission scanning electron microscope (SEM) was used to characterize  
173 the morphological structures of microsphere samples. Overall microsphere diameter was  
174 analyzed using SEM images. Micro CT was performed by ScanCo Associates, (ScanCo  $\mu$ CT 50,  
175 Brüttisellen, Switzerland) to measure local pore diameter. Microsphere porosity was calculated

176 using micro CT imaging, performed by ScanCo Associates. Microsphere porosity was determined  
177 using the following equation:

178

$$P_{scaffold} = \frac{V - V_p}{V} \times 100\%$$

179 where  $P_{scaffold}$  is the porosity of the microsphere batch,  $V$  is the total volume of the microsphere  
180 batch, and  $V_p$  is the volume of PLGA is equal to the mass divided by the density of PLGA ( $\rho = 1.3$   
181 g/cm<sup>3</sup>).

182 *Nanomechanical evaluation of microspheres*

183 To prepare a PLGA film for mechanical testing, 0.5 g of 50:50 PLGA (3.3% (w/v)), 0.75 g of 50:50  
184 PLGA (5% (w/v)) and 1 g of 50:50 PLGA (6.6% (w/v)) were each dissolved in 15 mL DCM and  
185 poured into a 25 mL glass beaker. Once the solvent evaporated, testing coupons were cut from  
186 each film and attached to titanium metal sections (10 mm x 10 mm x 0.25 mm) (Sigma, St. Louis,  
187 MO) with 100  $\mu$ l Elmer's glue (Westerville, OH). To prepare PLGA microspheres samples for  
188 nanomechanical testing, 100  $\mu$ l of Minwax polyacrylic (Upper Saddle River, NJ) was first applied  
189 to titanium sections using a spin coating system. A Dremel rotary tool (Dremel, Racine, WI) was  
190 used at 10,000 rpm for 5s to obtain a uniform polyacrylic layer before adherence of microspheres  
191 or films to the substrates is achieved. Samples were allowed to dry completely. Prior to  
192 nanoindentation experiments, some samples were rehydrated in neurobasal media for 1d, 2d, or  
193 7d. Samples were removed from the aqueous phase and carefully blotted before nanoindentation.

194 A Hysitron Triboindenter (Hysitron Inc., Minneapolis, MN, USA) nanoindenter with a pyramidal  
195 Berkovich diamond indenter tip (tip radius of 200 nm) was used to calculate the mechanical  
196 properties of three PLGA films (3.3% (w/v), 5% (w/v), 6% (w/v)) and PLGA microspheres (3.3%  
197 (w/v) in dry and hydrated states. After calibration with a standard fused quartz reference sample,  
198 an indentation depth was set at 1000 nm with a 20 nm/s displacement rate. The elastic modulus  
199 and hardness of each sample were measured at room temperature. A displacement depth of 1000  
200 nm was selected for all quasistatic nanoindentation experiments, resulting in reliable elastic  
201 property measurements free of substrate effects. Average values of elastic modulus and  
202 indentation hardness were calculated from the analysis of 30 unique microspheres. The  
203 estimation methods for determining elastic modulus (E) and indentation hardness (H<sub>IT</sub>) were  
204 based on Oliver and Pharr's methods.<sup>35-38</sup> These methods have been applied to make direct  
205 nanoindenter-based measurements of elastic and inelastic properties of soft materials such as  
206 human cells.<sup>39, 40</sup>

207 Fourier Transform Infrared Spectroscopy (FTIR) analysis

208 Transmission FTIR spectroscopy studies were performed using samples of polyvinyl alcohol  
209 (PVA), gelatin, PLGA, microspheres, microspheres coated with HAP for 12 h, and microspheres  
210 coated with HAP for 24 h. Samples were sandwiched between two KBr windows and placed in a  
211 universal sample holder. A Thermo Nicolet, Nexus, 870 spectrometer equipped with a KBr beam  
212 splitter was used for performing these experiments in the range of 4000 – 960 cm<sup>-1</sup>. A spectral  
213 resolution of 4 cm<sup>-1</sup> and 32 scans were used for each sample.

214 *Culture of human iPSCs, NSCs, and neural differentiation*

215 Two control human iPSC lines, NL5 (NCRM-5; kind gift from the iPSC Core Facility, NHLBI,  
216 Bethesda, MD) and Scui21 (Scui; kind gift from the NIH Stem Cell Unit, NINDS, Bethesda, MD),  
217 and one Smith-Lemli-Opitz syndrome (SLOS) patient-derived iPSC line (CWI 4F2; kind gift from  
218 Dr. Forbes Porter, NICHD, Bethesda, MD) were cultured and directed towards NSCs using a  
219 rosette-based assay as previously published.<sup>41, 42</sup> Following their derivation and expansion, NSCs  
220 were cultured on PLO+laminin coated 35 mm tissue culture dishes in NSC media (DMEM, 2 mM  
221 glutamine, B27 minus vitamin A, 20 ng/mL EGF, 20 ng/mL bFGF, 50 µg/mL Penicillin-  
222 streptomycin) supplemented with ROCK inhibitor Y27632 (10 µM). Media was changed every  
223 other day. Cells were passaged via incubation with Accutase (Life Technologies, Carlsbad, CA)  
224 at 37 °C for 3 - 5 min. Enzymatic reaction was stopped by adding NSC culture media with Y27632,  
225 followed by centrifugation at 1,500 rpm. Cells were divided evenly between two new PLO+laminin  
226 coated culture dishes (approximately 2.5 – 3 x 10<sup>6</sup> cells per dish).

227 To induce neural differentiation, NSCs were collected from 35 mm cell expansion dishes as  
228 described above. Upon resuspension in NSC media, cells were plated in 24- or 96-well plates  
229 coated with PLO+laminin (ThermoFisher Scientific, Waltham, MA) or Lab-Tek Nunc 4-well  
230 chamber glass slides coated with PLO + laminin. Cells were maintained in NSC media  
231 supplemented with 10% fetal bovine serum (FBS) for 4 days and then changed to neural  
232 differentiation media (Neurobasal media, B27 with vitamin A, 10 ng/mL GDNF, 10 ng/mL BDNF,  
233 2 mM glutamine, 50 µg/mL penicillin-streptomycin) for the duration of differentiation. For  
234 neurosphere culture, NSCs were collected via Accutase and plated at 150,000 cells per well in a  
235 96-well, round-bottom ultra-low attachment plate. Neurospheres were maintained in suspension  
236 in NSC media supplemented with FBS for 4 days and then changed to NSC differentiation media  
237 for the duration of each experiment. For microsphere culture of NSCs, 100 µg of microspheres  
238 were added to each round-bottom well of an ultra-low attachment 96-well plate. Upon

239 resuspension in NSC media, 150,000 cells were passively seeded onto the microspheres.  
240 Microspheres were cultured in NSC media supplemented with FBS for 4 days and then changed  
241 to neural differentiation media for the duration of each experiment. All culture plates and dishes  
242 were cultured at 37 °C with 5% CO<sub>2</sub>.

243 *Serum impact on NSC microsphere attachment*

244 Microspheres were immersed in 70% ethanol for 60 min on an orbital shaker set at 100 rpm.  
245 Microspheres (1 mg) were transferred to flat-bottom, low-attachment 24-well plate before NSCs  
246 were seeded onto microspheres (150,000 cells per 1 mg of microspheres per well) in NSC media.  
247 Serum supplemented groups received 10% FBS. The cells/scaffolds were cultured in a 24-well  
248 plate at 37° C with 5% CO<sub>2</sub>.

249 *Evaluation of substrates for NSC microsphere attachment*

250 Microspheres were divided into fractions and sterilized as previously mentioned. Microspheres  
251 were coated with PLO + laminin as above. Microspheres receiving Matrigel coating were placed  
252 into a sterile glass vial and incubated in either Matrigel for 2 h on an orbital shaker set for 50 rpm  
253 at room temperature. Uncoated or substrate coated microspheres were transferred to wells of a  
254 24-well plate before NSC control line cells were seeded into the scaffold (150,000 cells per 1 mg  
255 of microspheres). Cells/scaffolds were cultured in a 24-well plate at 37 °C with 5% CO<sub>2</sub>.

256 *Astrocyte generation from iPSC-derived NSCs*

257 70,000 NSCs were plated onto 35 mm PLO+laminin coated tissue culture dishes and maintained  
258 in neural differentiation at 37 °C with 5% CO<sub>2</sub> through d14. On d14, cells were collected via  
259 Accutase, transferred to 35 mm tissue culture plates coated with 25 µg/mL poly D-lysine (PDL)  
260 (Sigma Aldrich, St. Louis, MO), and media was changed to astrocyte differentiation media  
261 (DMEM/F12, 2 mM Glutamine, 10% FBS, and 1% penicillin-streptomycin). Media changes  
262 occurred every 48 h through d28. On d28, cells were collected with 0.25% Trypsin-EDTA and  
263 transferred to a PDL-coated T25 tissue culture flask for expansion. Astrocytes were expanded  
264 and passaged with Trypsin-EDTA for an additional 30 – 45 days as needed prior to use.

265 *Human umbilical vein endothelial cell (HUVEC) microsphere culture*

266 HUVECs obtained from Lonza (Walkersville, MD) were plated on T25 flasks and cultured with  
267 Endothelial Basal Medium-2 (cat# 00190860) (Lonza, Walkersville, MD) at 37 °C with 5% CO<sub>2</sub>.<sup>34</sup>  
268 HUVECs were harvested from the flask by rinsing with PBS, adding 2 mL of 0.05% Trypsin-EDTA  
269 to the flask, and incubating at 37° C for 3-5 min. Cells were centrifuged at 1,500 rpm for 5 min,

270 supernatant was aspirated, and the cell pellet was resuspended in neural differentiation media  
271 before adding to microspheres.

272 *Multilineage co-culture using microsphere scaffolds*

273 Microsphere samples were immersed in 70% ethanol for 60 min on an orbital shaker set at 100  
274 rpm. Microspheres (100 µg) were added to each well of an ultra-low attachment 96-well plate. On  
275 d0, NSCs were collected from 35 mm cell expansion dishes via Accutase as described above.  
276 Upon resuspension, NSCs were passively seeded onto 100 µg of microspheres. On d2,  
277 astrocytes were passively seeded onto the NSC-only microspheres. On d5, HUVECs were added  
278 to each NSC+astrocyte scaffold. All groups were cultured in NSC differentiation media at 37 °C  
279 with 5% CO<sub>2</sub>.

280 *Immunofluorescent imaging of scaffold cultured cells*

281 The cell lineage of differentiating NSCs was visualized by immunofluorescence using primary and  
282 secondary antibodies. Cell-based spheroids and cell-seeded microspheres were fixed in 4%  
283 paraformaldehyde for 20 min, rinsed with 1x PBS, and permeabilized with 0.1% TritonX-100 for  
284 20 min. Samples were subsequently blocked with 5% bovine serum albumin containing 0.1%  
285 TritonX-100 in PBS for 60 min before the following primary antibodies were added: chicken anti-  
286 GFAP (Novus Biologicals, NBP1-05198, 1:2000), mouse anti-βIII-Tubulin (Millipore, MAB1637,  
287 1:1000), mouse anti-human Nestin (Millipore, MAB5326, 1:2000), mouse anti-MAP2 (Synaptic  
288 Systems, 188 011, 1:2000), rabbit anti-Neurofilament, medium chain (Novus Biologicals, NB300-  
289 133, 1:2000), rabbit anti-SOX2 (Cell Signaling, 3579S, 1:400), mouse anti-Ki67 (Abcam,  
290 ab15580, 1:2000), mouse anti-CD31 (Abcam, ab9498, 1:1000). Samples were incubated with  
291 primary antibody at 4 °C overnight. Following overnight incubation, samples were incubated for  
292 60 min with the following secondary antibodies diluted in blocking buffer: AlexaFluor 555 rabbit  
293 anti-mouse IgG (Life Technologies, A21427), AlexaFluor 555 donkey anti-rabbit IgG (Life  
294 Technologies, A31572), AlexaFluor 488 goat anti-mouse IgG (Life Technologies, A11001),  
295 AlexaFluor 488 goat anti-rabbit IgG (Life Technologies, A11008), or AlexaFluor 488 goat anti-  
296 chicken IgG (Life Technologies, A11039). All secondaries were diluted 1:500. After rinsing,  
297 Fluoromount-G with DAPI was added. Samples were imaged using a confocal laser scanning  
298 microscope (Olympus Fluoview FV1200, Olympus, Japan).

299 *Hematoxylin and eosin staining of scaffold cultures*

300 Scaffolds were fixed in 10% neutral buffered formalin and processed on a Leica 300 ASP tissue  
301 processor. Tissues were embedded in paraffin and serially sectioned at 5 µm thickness. Slides  
302 were stained with hematoxylin and eosin on a Sakura Tissue-Tek automated H&E staining  
303 instrument. The program runs as follows: de-paraffinize and rehydrate tissue, stain in Gill's III  
304 hematoxylin, differentiate with running tap water, blue in ammonia water, counterstain in eosin,  
305 and dehydrate and clear. All images were taken on a Nikon NiE microscope using a Nikon DS-  
306 Fi2 camera and 20x/0.75 PlanApo λ objective.

307 *Bovine serum albumin (BSA) loading and release from microspheres*

308 Microspheres were coated with HA as discussed above with minor changes. BSA (2.5 mg) was  
309 added to 25 mL of SBF in each combination (+P1-P2; -P1+P2; +P1+P2) and incorporated into  
310 the HA. When the microspheres were collected after each HA deposition phase, the supernatant  
311 was saved to analyze BSA remaining in the solution. Microspheres were also rinsed with 1 mL of  
312 DI water and the rinse solution was saved to calculate incorporation efficiency. To measure the  
313 amount of BSA incorporated into the HA microspheres, four groups of BSA-loaded microspheres  
314 were immersed in 0.5M EDTA solution and vortexed for 1 min and centrifuged at 2,000x G for 2  
315 min. Incorporation efficiency was determined by calculating the BSA remaining in the SBF  
316 supernatant, the BSA in the rinse solution, and the BSA released from microspheres. To model  
317 release, 10 mg of BSA-HA microspheres were added to microcentrifuge vials with 1 mL PBS and  
318 placed into an incubating shaker set for 100 rpm and 37 °C. At predetermined time points (30  
319 min, 1 h, 2 h, 5 h, 12 h, d1, d2, d3, d7, d10, and d15), 500 µL of PBS eluent was removed and  
320 500 µL fresh PBS was added to the tube. Analysis of BSA release was performed using a Pierce™  
321 bicinchoninic acid (BCA) protein assay kit (Thermo Fisher, Waltham, MA) per manufacturer's  
322 instructions.

323 *bFGF loading, release, and impact on cell viability*

324 Microspheres were coated with HA as previously discussed. 20 ng/mL bFGF was added to both  
325 SBF phases (+P1+P2) and incorporated into the crystal matrix. NSCs were passively seeded onto  
326 100 µg of microspheres. Microsphere-based scaffolds were cultured in NSC media for 14 days at  
327 37 °C with 5% CO<sub>2</sub>. At each time point (d1, d4, d7, and d14), bFGF-HA scaffolds were analyzed  
328 by MTS assay to determine the amount of proliferation compared to other 2D and 3D groups.  
329 Each group was cultured in triplicate and 50% of the cell culture media was replenished every 48  
330 h. Cell viability was quantitatively analyzed using the CellTiter 96 Aqueous One Solution Cell  
331 Proliferation Assay (MTS, Promega, USA) according to the manufacturer's instruction. In brief,

332 after culturing for 1, 4, 7, or 14 days in round-bottom, ultra-low attachment 96-wells, the culture  
333 medium was removed, fresh medium with 10% MTS solution was then added, and incubated at  
334 37 °C with 5% CO<sub>2</sub> in the dark for 1 h. Each biological replicate was analyzed in quadruplicate by  
335 removing 100 µL volumes from each well. The absorbance was measured at 490 nm using a  
336 microplate reader (Infinite M200, Tecan, USA). Cell viability was expressed as cell number  
337 calculated by the slope of a standard curve prepared by culturing NSCs at densities from 50,000  
338 - 500,000 on PLO+laminin coated wells of a 24-well plate (data not shown).

339 **Statistical analyses**

340 To determine the statistical significance of observed differences between the study groups, a two-  
341 tailed Student's t-test was applied to the control group and each experimental group. A value of  
342 p<0.05 was considered to be statistically significant. Values are reported as the mean ± one  
343 standard deviation (SD). Microscopic images across treatments were imaged using equivalent  
344 laser power and exposure times.


345 **Ethics, human subjects research statement**

346 All research performed using human cell lines was determined to not constitute human subjects  
347 research by the institutional review board of Sanford Research.

348 **Results**

349 **Preparation of a microsphere scaffold for culture of iPSC derivatives is rapid and tunable**

350 To create a scaffold for culture of iPSC derivatives, we utilized a double emulsion and porogen  
351 leaching technique to yield a highly uniform poly(lactic-co-glycolic) (PLGA) microsphere matrix  
352 with interconnected pores and >88% overall porosity. Gelatin was utilized as the sacrificial  
353 porogen to create spherical pores within the PLGA matrix. Through optimization of each step  
354 within the preparation process, we have created a stable, consistent microsphere structure  
355 (**Figure 1A**). **FTIR analysis of the various materials utilized for microsphere generation and**  
356 **coating was performed to verify production material chemistries in comparison to spectra within**  
357 **the final microsphere product (Supplemental Figure 1)**. Through variations in the speed of mixing  
358 the gelatin/PLGA during the emulsion process, we were able to control microsphere diameter  
359 (**Figure 1B,C**). Using a 400 rpm mixing step, microsphere diameter exhibited reduced variability  
360 and the majority remained within the 100 – 250 µm range (**Figure 1D,E**). Based upon a mean  
361 microsphere diameter achieved, we utilized a 400 rpm mixing speed for all subsequent



362


363 **Figure 1. Preparation and characterization of the microsphere scaffold.** (A) Illustration of the double  
 364 emulsion and porogen leaching process used to prepare porous PLGA microspheres; (B) SEM image of  
 365 a single porous microsphere (scale bar = 100  $\mu$ m); (C) Defined stirring speed during secondary emulsion  
 366 dramatically impacted mean microsphere diameter. (n=3 per treatment, each group contained 250  
 367 microspheres); (D) SEM Image of a representative batch of microspheres (scale bar = 500  $\mu$ m); (E)  
 368 Distribution of microsphere size across multiple batch preparations using a stirring speed of 400 rpm (n =  
 369 3 biological replicates, each replicate contained 250 microspheres); (F) Micro CT image of internal  
 370 microsphere structure (scale bar = 1 mm). (G) Local pore diameter as calculated by micro CT. Error bars  
 371 represent  $\pm$  standard deviation.

372 microsphere assays. Microspheres were packed into a micro CT chamber with a volume of 3.14  
373 mm<sup>3</sup> (**Figure 1F**). Analysis revealed a local pore diameter of 50 ± 35 µm, >88% porosity, and an  
374 open, interconnected pore structure (**Figure 1G**). The process described in this study optimizes  
375 the microsphere porosity, size distribution, and reproducibility for use as a scalable platform for  
376 3D cell culture applications.

377 *The mechanical properties of microsphere scaffolds are impacted by hydration*

378 Nanoindentation assays were performed to determine the mechanical properties of PLGA  
379 samples. The nanomechanical properties of PLGA thin-film (dry state) and microspheres (both  
380 dry and hydrated states) were determined as a function of hydration (T<sub>h</sub>). The load-displacement  
381 response for the PLGA thin-film and microspheres were measured in displacement-controlled  
382 loading and unloading mode. We determined the average elastic modulus (E) for non-hydrated  
383 PLGA thin-films of 3.3% (w/v), 5% (w/v), or 6.6% (w/v) was E = 1.48, 0.619, and 0.129 GPa,  
384 respectively. The indentation hardness (H<sub>IT</sub>) obtained for these films equated to 34.6 ± 2.4 MPa,  
385 15 ± 1.1 MPa, and 6.2 ± 0.4 MPa for 3.3% (w/v), 5% (w/v), and 6.6% (w/v) non-hydrated PLGA  
386 films, respectively. By comparison, the elastic modulus and indentation hardness values for non-  
387 hydrated PLGA microspheres (3.3% (w/v)) were significantly lower (E = 76.6 ± 10 MPa and H<sub>IT</sub> =  
388 5.4 ± 0.5 MPa, respectively) than non-hydrated thin-film (3.3% (w/v)), demonstrating the  
389 mechanical impact of porous architecture (**Figure 2A**). The force-displacement response from  
390 PLGA microsphere indentation captures both the microstructural response of the PLGA polymer  
391 structure as well as the pore spaces. The highly porous microspheres produced significantly lower  
392 mechanical properties compared to the film. The elastic modulus and indentation hardness of the  
393 PLGA microspheres (3.3% (w/v)) decreased as hydration increased (**Figure 2B, C**). For hydrated  
394 microspheres, a nearly 40% decrease in modulus (**Figure 2B**) was observed after 24 h hydration  
395 relative to the dry state (E = 76.6 ± 10 MPa). The modulus dropped to E = 29.3 ± 2.8 MPa, 24.9  
396 ± 1.3 MPa and 14.9 ± 1.5 MPa on d1, d2, and d7, respectively. The hardness values also  
397 decreased similarly with increased hydration (**Figure 2C**). While H<sub>IT</sub> = 5.4 ± 0.5 MPa in the dry  
398 state, H<sub>IT</sub> decreased over time with prolonged hydration (H<sub>IT</sub> = 2.4 ± 0.3 MPa, 1.7 ± 0.1 MPa and  
399 1.44 ± 0.2 MPa on d1, d2 and d7, respectively). These data demonstrate our PLGA-based scaffold  
400 exhibits mechanical properties that become more tissue-like with incubation in aqueous solutions  
401 such as culture media.

402 *Optimization of iPSC-derived NSC scaffold attachment*



403

404 **Figure 2. Hydration of the microsphere scaffold (3.3% (w/v)) shifts load-displacement curves, the**  
 405 **elastic modulus, and indentation hardness as a function of time. (A) Load-displacement response for**  
 406 **the PLGA thin-film and microspheres in a dry state demonstrates the softening effect of the porous**  
 407 **microstructure of microspheres. (B), (C), (D) Deformation response and mechanical properties of the**  
 408 **hydrated PLGA microspheres compared to the dry state with degradation. All error bars for elastic modulus**  
 409 **measurements (panel B) and indentation hardness (panel C) are represented as ± standard deviation.**

410


411

412

413

414

415



416 **Figure 3. Assay schema for validating the use of a PLGA-based microsphere system for neural cell**  
 417 **models.** iPSC-derived NSCs were either cultured in traditional 2D systems, grown as self-aggregating 3D  
 418 neurospheres, or seeded onto 3D microsphere based structures. Cultures were then analyzed for various  
 419 cellular parameters including attachment, proliferation, differentiation, and co-culture.

420

421

422

423

424

425

426

427

428

429

430


431

432

433

434 We next sought to determine whether our newly developed PLGA-based material could function  
435 as a cellular scaffold and model for neurodevelopment. Beginning with the addition of iPSC-  
436 derived NSCs to the scaffold, we outlined a series of assays to qualify the ability of our PLGA-  
437 based material to promote NSC attachment, proliferation, differentiation, and support co-culture  
438 studies (**Figure 3**). To first determine the efficiency of iPSC-derived NSC attachment onto our  
439 PLGA microsphere surface, NSCs were cultured with unmodified PLGA microspheres in the  
440 presence or absence of FBS for 1, 3, 5, or 7 days (**Figure 4A**). The addition of serum has  
441 previously been shown to aid in the attachment of neural cell types to culture matrices.<sup>43-47</sup>  
442 Through balancing the positive impact on NSC attachment while minimizing the influence of FBS  
443 on neural differentiation, neural differentiation and tissue modeling could be optimized. NSCs  
444 were passively seeded onto unmodified PLGA microspheres in the presence or absence of FBS  
445 and cultured for 7 days before being fixed for immunocytochemistry (ICC) (**Figure 4A**). Analysis  
446 of two distinct NSC lines revealed that serum supplementation for any length of time increased  
447 the number of nuclei per microsphere compared to non-FBS supplemented (**Figure 4B,C**).  
448 Additionally, F-actin expression, as a measure of cytoskeleton formation, was increased by NSC  
449 serum supplementation (**Figure 4D**). While these data suggest short-term exposure to serum  
450 increases NSC microsphere attachment, substrates which avoid the inhibitory effects of serum  
451 on neural differentiation may benefit NSC properties.<sup>48</sup>

452 Through serum-free culture of embryoid body-like aggregates with quick reaggregation (SFEbq),  
453 *in vitro* neuronal differentiation can be achieved in the absence of extrinsic neural induction  
454 factors.<sup>3, 18, 49, 50</sup> It is also established that growth factor and protein-rich hydrogels such as Matrigel  
455 support the development of 3D neural cultures.<sup>51</sup> Since our biomaterial-based methodology  
456 supports 3D self-organization and the minimization of undefined factors, we compared the  
457 responses of NSCs cultured on uncoated microspheres to microspheres coated with two different  
458 neural supportive substrates: PLO+laminin and Matrigel. Confocal microscopy images  
459 demonstrated NSCs attached to either uncoated, PLO+laminin-coated, or Matrigel-coated  
460 microspheres (**Figure 5A**). NSCs demonstrated an increase in cell number over the measured  
461 time course across all conditions (**Figure 5B**). Calculations of F-Actin produced per cell showed  
462 a relatively consistent trend over the time course (**Figure 5C**).<sup>52</sup> While NSCs exhibited 60-70%  
463 positivity for the proliferation marker Ki67 across all culture conditions early on (**Figure 5D**), a  
464 universal reduction in Ki67<sup>+</sup> cells was subsequently observed across all conditions, suggesting  
465 terminal differentiation has likely begun (**Figure 5D**). These results are consistent with previous  
466 *in vitro* 3D culture models demonstrating a reduction in Ki67 expression in the early stages of  
467 differentiation.<sup>53</sup> Our data demonstrate that cells cultured on uncoated or PLO+laminin coated



468

469 **Figure 4. Serum improves attachment and cytoskeleton production by microsphere-cultured**  
470 **NSCs.** (A) Diagram depicting the experimental design for serum supplemented media exposure. (B)


471 Confocal images of NSCs on uncoated microspheres after 7 days of serum supplementation; nuclei

472 identified with DAPI and F-actin filaments labeled with Phalloidin Texas-red (scale bar = 300  $\mu$ m). (C)

473 Nuclei counts of NSCs after varying duration of serum supplementation; n = 3 biological replicates per

474 group. (D) Quantified F-actin per cell by Phalloidin Texas-red after varying durations of serum

475 supplementation; n = 3 biological replicates per group. Error bars represent  $\pm$  standard deviation. \*  
476 indicates significant increase ( $p < 0.05$ ) in Scui NSCs compared to serum-free control; # indicates  
477 significant increase ( $p < 0.05$ ) in NL5 NSCs compared to serum-free control.



478

479

480 **Figure 5. Neural supportive substrates promote proliferation and cytoskeletal production from**  
 481 **microsphere-cultured NSCs.** (A) Confocal images of Scui NSCs at d7 on uncoated microspheres (top  
 482 panel), PLO+laminin coated microspheres (middle panel), and Matrigel coated microspheres (bottom  
 483 panel) (scale bar = 200  $\mu$ m). Arrowheads indicate selected Ki67 positive cells. (B) Increasing cell counts  
 484 on uncoated, PLO+laminin-coated, and Matrigel-coated microspheres over 7 days. (C) The volume of F-  
 485 actin per cell on d7 remained constant despite increasing cell number. (D) No significant difference in the  
 486 percentage of Ki67 positive cells was observed between uncoated and coated microspheres. n = 15 (3  
 487 biological replicates and 5 image fields per group). Error bars represent  $\pm$  standard deviation.


488

489 microsphere scaffolds display comparable characteristics to those exposed to the poorly defined  
490 supportive effects of Matrigel.

491 *A scaffold-based model supports neural differentiation of both control and patient-derived iPSC*  
492 *models*

493 Recent studies have questioned the quality of 2D monolayer neural culture due to the inability of  
494 cells to become polarized on rigid, flat surfaces.<sup>19, 54</sup> To evaluate the differentiation of iPSC-derived  
495 NSCs cultured on a microsphere scaffold to traditional differentiation models, we compared the  
496 differentiation of control and patient-derived iPSCs within a two-dimensional system, as self-  
497 aggregating neurospheres, and cultured on microsphere scaffolds. The CWI 4F2 patient iPSC  
498 line is a model for the cholesterol synthesis disorder Smith-Lemli-Opitz syndrome, a rare disease  
499 where subjects exhibit significant neurological malformations.<sup>41, 55</sup> We previously demonstrated  
500 this cell line exhibits stem cell defects and accelerated neuronal differentiation.<sup>41</sup> After 7 days of  
501 differentiation, we verified the multilineage differentiation of both control and patient-derived NSCs  
502 using immunocytochemistry. Cultured cell lines exhibited extensive expression of the human  
503 neural progenitor marker hNestin, pan-neuronal marker  $\beta$ III-tubulin, the neuronal dendritic marker  
504 microtubule associated protein-2 (MAP2), and the astrocyte marker glial fibrillary acidic protein  
505 (GFAP) (**Figure 6A-C**). Compared to traditional two-dimensional culture, spheroid culture allowed  
506 for abundant hNestin<sup>+</sup> neural progenitors but very little NF-M expression (**Figure 6D,E**). In  
507 scaffold-based culture, control (NL5) NSCs showed abundant hNestin expression, F-Actin and  
508 high expression of NF-M (**Figure 6F,G**). Patient (CWI 4F2) neurospheres exhibited both high  
509 levels of Sox2 and NF-M compared to NL5, in agreement with the previously published  
510 accelerated neuronal differentiation phenotype in this model (**Figure 6H,I**).<sup>41</sup> In comparison, CWI  
511 4F2 cultured scaffolds demonstrated a mixed neural lineage, including Sox2<sup>+</sup> and hNestin<sup>+</sup> NSCs,  
512 as well as extensive NF-M expression (**Figure 6J,K**). Analysis of F-actin also demonstrated  
513 increased cytoskeleton formation within both control and patient-derived cells on scaffold vs.  
514 neurospheres (**Figure 6D,F,H,J**).

515 After 28 days of differentiation, NSCs cultured on two-dimensional PLO+laminin coated coverslips  
516 underwent considerable morphological change. While extensive GFAP<sup>+</sup> astrocytes were  
517 observed by d28, differentiated neurons formed cell clumps and demonstrated loss of cell  
518 adhesion associated with diminished cell health (**Figure 7A,B**). While spheroid cultures  
519 maintained a uniform cell distribution and overall structure, spheroid size was unchanged  
520 compared to d7. Further, spheroids exhibited increased NF-M<sup>+</sup> neurons compared to d7 while  
521 maintaining high F-Actin and hNestin levels (**Figure 7C,D**). However, GFAP expression was not




522

523 **Figure 6. Microsphere-cultured control and patient-derived iPSC derivatives exhibit early neuronal**  
 524 **lineage commitment.** Comparison of control (NL5) and patient (CWI 4F2) models in 2D, 3D neurospheres,  
 525 and 3D microspheres after 7 days differentiation. (A,B) NSCs exhibit low amounts of NF-M and F-Actin, but  
 526 abundant hNestin expression. (C) 2D differentiation produces extensive MAP2 expression. (D,E) Control  
 527 NSCs cultured as scaffold-free neurospheres labeled by ICC for hNestin, F-Actin, and DAPI (D) or hNestin,  
 528 NF-M, and DAPI (E). (F,G) Control NSCs cultured as cellular scaffolds labeled by ICC for hNestin, F-Actin,  
 529 and DAPI (F) or hNestin, NF-M, and DAPI (G). (H,I) CWI 4F2 NSCs cultured as a scaffold-free neurosphere  
 530 labeled by ICC for Sox2, F-Actin, and DAPI (H) or hNestin, NF-M, and DAPI (I). (J,K) CWI 4F2 NSC  
 531 scaffolds labeled by ICC for Sox2, F-Actin, and DAPI (J) or hNestin, NF-M, and DAPI (K) (scale bar = 300  
 532 μm).

533

534

535




536 **Figure 7. Microsphere culture allows NSC differentiation to neuronal and glial lineages.** (A,B) 28 day  
 537 differentiation in 2D conditions generates extensive neuronal (NF-M,  $\beta$ III-tubulin) and astrocyte (GFAP)  
 538 formation with loss of NSCs (hNestin) (DAPI nuclear counterstain). (C,D) Spheroid culture maintains NSCs  
 539 (hNestin) over 28 days with neuronal (NF-M) and cytoskeletal (F-actin) formation. (DAPI nuclear  
 540 counterstain). (E,F) Microsphere culture allows for expansion and cytoskeletal production of NSCs (hNestin,  
 541 F-actin), as well as robust differentiation to neuronal (MAP2) and astrocytic (GFAP) lineages. (scale bar =  
 542 300  $\mu$ m).

543 observed in spheroids. In comparison to spheroid cultures, the diameter of microsphere scaffold  
544 cultures was significantly increased on d28 of differentiation (**Figure 7E,F**). Scaffold-based  
545 cultures also demonstrated extensive glial differentiation, as exhibited by GFAP<sup>+</sup> cell types.  
546 Expansive glial differentiation within scaffold-based cultures was not at the expense of neuronal  
547 differentiation, as evidenced by extensive MAP2 expression. Using immunohistochemistry, we  
548 further determined that scaffold-based cultures exhibited integration of NSC-derived cells  
549 throughout the microsphere (**Supplemental Figure 2**). H&E staining demonstrated broad  
550 distribution of cells throughout the scaffold, validating the ability of cells to migrate from the  
551 scaffold's exterior surface. Overall, these assays demonstrate that our microsphere matrix  
552 provided a chemically defined, neural-supportive microenvironment which allows expansion,  
553 migration and multilineage differentiation of both control and patient-derived NSCs.

554 Recent work has demonstrated co-culture of endothelial cells with iPSC-derived models supports  
555 neural health and maturation.<sup>56, 57</sup> To demonstrate the capacity of our scaffold-based system for  
556 multi-lineage co-culture, NSCs, astrocytes, and endothelial cells were sequentially seeded onto  
557 a PLO+laminin coated microsphere scaffold. NSCs were first seeded onto microspheres in ultra-  
558 low attachment 96 well plates, followed by astrocytes and finally HUVECs (**Figure 8A**). As  
559 demonstrated by expression of  $\beta$ III-tubulin, GFAP, and CD31 on d7 of co-culture, the scaffold  
560 allows for attachment, survival, and integration of each cell type (**Figure 8**). F-actin expression,  
561 identified by Phalloidin Texas-red, and nuclear counterstaining demonstrate broad cell distribution  
562 and cytoskeletal formation throughout the microsphere-based scaffold (**Figure 8L,O**). ICC  
563 demonstrated that astrocytes, neurons, and HUVECs were still identifiable within the cellular  
564 scaffold on d28 of co-culture (**Figure 8F,K,P**). Increased expression of NF-M, GFAP and CD31  
565 on d28 suggests increased neuronal maturation and proliferation of astrocytes and HUVECs  
566 (**Figure 8F,K,P**). Further, maintenance of hNestin<sup>+</sup> cells at d28 suggests continued NSC  
567 maintenance within this co-culture scaffold. These data further demonstrate the ability of the  
568 microsphere scaffold for robust co-culture of neural, glial, and endothelial cells, representing a  
569 critical initial step towards the formation of mature, nutrient-rich, and vascularized 3D structures  
570 using this material<sup>58</sup>.

571 *Microspheres can function as a platform for sustained growth factor release*

572 Neural differentiation of iPSCs requires frequent exogenous supplementation of defined cocktails  
573 of growth factors and cytokines to promote cell proliferation, differentiation, and tissue  
574 organization. To determine if microspheres could function in both cellular support and growth




575

576 **Figure 8. Microsphere-based scaffolds support the co-culture of NSCs, astrocytes, and HUVECs.**  
 577 (A) Cell seeding and ICC analysis timeline. Confocal images displayed as maximum projections of iPSC-  
 578 derived NSCs, astrocytes, and HUVECs within scaffold. (B-E) d7 ICC for neurons ( $\beta$ III-tubulin) and  
 579 astrocytes (GFAP). (F) d28 ICC for neurons ( $\beta$ III-tubulin) and astrocytes (GFAP). (G-J) d7 ICC for HUVECs  
 580 (CD31) and astrocytes (GFAP). (K) d28 ICC for HUVECs (CD31) and cytoskeletal formation (F-actin). (L-  
 581 O) d7 ICC for cytoskeletal formation (F-actin) and mature neurons (NF-M). (P) d28 ICC for neural  
 582 progenitors (hNestin) and mature neurons (NF-M). DAPI nuclear counterstain is also shown. (Scale bar =  
 583 300  $\mu$ m).

584

585



586 **Figure 9. Hydroxyapatite coated microspheres allow for protein loading and release.** (A) An SEM  
 587 image of a PLGA microsphere covered in hydroxyapatite nucleation crystals after immersion in SBF  
 588 phase I (P1) solution (scale bar = 50  $\mu$ m). (B) An SEM image of a PLGA microsphere covered in mature  
 589 hydroxyapatite crystals after immersion in SBF phase II (P2) solution (scale bar = 50  $\mu$ m). (C) Greater  
 590 amounts of BSA were released from P1+P2 compared to P1 only or P2 only after 360 h in solution (n =  
 591 4).

592


593

594

595

factor release, microspheres were layered with hydroxyapatite crystals via SBF. While hydroxyapatite has traditionally been utilized for osteogenic differentiations<sup>59-61</sup>, recent work has demonstrated hydroxyapatite also promotes neural differentiation and functional neuronal development through enhanced Ca<sup>2+</sup> signaling.<sup>62, 63</sup> HA was deposited onto the entire exposed exterior and interior surfaces of the microsphere, allowing crystal deposition without pore occlusion (**Figure 9A,B**). The first SBF phase deposited on the microsphere surface (HA1) acts as a nucleation site, while second phase deposition creates an additional layer (HA2) (**Figure 9A,B**). To model the capacity of the two HA layers to entrap and release proteins, BSA was added to SBF phase 1 and phase 2 solutions. BSA entrapment was evaluated in three different combinations: BSA added to SBF phase 1 only (P1 only), BSA added to SBF phase 2 (P2 only), or BSA added to both SBF phases (P1+P2). While P1 only incorporation of BSA was relatively inefficient (7.2%), P2 only (34.5%) and P1+P2 (56.3%) demonstrated robust protein incorporation into HA layers. BSA release following P1+P2 entrapment was also highly efficient (96.9 ± 3.56%) (**Figure 9C**). The release rates among the three groups varied in relation to their incorporation efficiency. The P1 only group (7.2% incorporation efficiency) had an overall release rate of 0.008 µg/min during the 360-hour release timeframe. The P2 only group (34.5% incorporation efficiency) had an overall release rate of 0.04 µg/min over 360 hours and the P1+P2 group (56.3% incorporation efficiency) had an overall release rate of 0.14 µg/min.

After verifying that an entrapped protein could be loaded and released in a controlled and sustained manner, we sought to determine if the scaffold could support loading and release of multiple molecules. Two biomolecules were loaded into hydroxyapatite-coated microspheres: a FITC-conjugated peptide was loaded into phase 1 HA and AlexaFluor647-conjugated BSA was incorporated into phase 2 HA. NSCs were seeded onto the scaffold following protein entrapment, followed by imaging for FITC, AlexaFluor647, and DAPI counterstained NSC nuclei (**Figure 10A**). NSCs attached onto the surfaces of all HA-coated microspheres and formed robust cytoskeletal projections across the scaffold (**Figure 10B**). To determine the bioactivity of entrapped biomolecules, bFGF was entrapped in both phases of the HA crystal matrix (P1+P2). The loading of bFGF into both HA layers did not interfere with the porous structure of the microsphere, as the microsphere matrix was covered in HA crystals (**Figure 10C**). While bFGF-loaded crystals appeared somewhat flattened compared to HA crystals without loading (**Figure 10D**), the bFGF-entrapped scaffold demonstrated increased NSC proliferation in scaffold cultures compared to standard 2D culture (**Figure 10E**). These data demonstrate the microsphere scaffold can be utilized for entrapment and release proteins of interest in a sustained manner, providing direct trophic factor support to seeded cells.



630 **Figure 10. Protein-loaded and hydroxyapatite-coated microspheres supply growth factors directly**  
631 **to scaffold-cultured NSCs.** (A) Confocal images of NSCs on an HA-microsphere-based scaffold with  
632 merged ICC channels showing FITC-peptide in phase I HA, BSA-AlexaFluor 647 in phase II HA, and cell  
633 nuclei counterstained with DAPI; scale bar = 250  $\mu$ m. (B) Confocal images of NSCs on an HA-  
634 microsphere-based scaffold with merged ICC channels showing F-actin filaments identified with  
635 Phalloidin Texas-red and nuclei counterstained with DAPI; scale bar = 250  $\mu$ m. C) SEM image of a  
636 microsphere with bFGF incorporated into HA matrix (+P1+P2) (scale bar = 25  $\mu$ m); (D) SEM image of  
637 NSC cultured microsphere scaffold after 5 days. Scaffold contains bFGF incorporated into HA. (scale bar  
638 = 200  $\mu$ m). (E) bFGF released directly from HA promoted NSC proliferation over 14 days comparably to  
639 bFGF-supplemented media. Error bars represent  $\pm$  standard deviation.

640 **Discussion**

641 PLGA has been widely used as a biomaterial to support and direct cell fate through various 3D  
642 tissue engineering scaffold fabrication techniques such as electrospinning, soft lithography, gas  
643 foaming, particle leaching, supercritical CO<sub>2</sub>, phase separation, 3D printing, and freeze-drying.<sup>64</sup>  
644<sup>70</sup> Polymeric and composite materials utilizing PLGA have been used to align tenocytes to support  
645 tendon repair, induce chondrogenesis of rabbit mesenchymal stem cells, promote hepatogenesis  
646 of human adipogenic stem cells, and differentiation of canine smooth muscles cells.<sup>64, 66</sup> PLGA  
647 scaffolds were used with and without the addition of transforming growth factor- $\beta$ 3 to support the  
648 delivery and differentiation of mesenchymal stem cells towards articular cartilage *in vivo*.<sup>71</sup> Our  
649 work has demonstrated PLGA microspheres provide a multifunctional, 3D cell culture platform  
650 also capable of loading and releasing proteins, peptides, and other growth factors. By  
651 incorporating biocompatible materials, using defined starting numbers of stem cells, and providing  
652 a chemically defined environment, our scaffold platform addresses some of the current challenges  
653 limiting the utility of 3D cell culture.<sup>15</sup> The microsphere scaffold developed here can be readily  
654 produced in high numbers, the product is shelf-stable for future use, and the final microsphere  
655 diameter is tunable during preparation. We have further demonstrated this system can be used  
656 to allow effective neural differentiation in three dimensions. Though Young's modulus of PLGA is  
657 higher than the presumptive ECM of the brain, substrate stiffness differs between areas of the  
658 brain and within glial subtypes. Studies have reported a stiffness range from 0.1 to 16 kPa across  
659 brain regions.<sup>1, 11, 72</sup> Substrate stiffness also influences neural subtype differentiation. Neuronal  
660 differentiation favors softer substrates (100-500 Pa) while stiffer substrates (1-10 kPa) favor glial  
661 differentiation.<sup>1, 72</sup> Rat NPCs cultured on surfaces with stiffness up to 35 kPa were not affected by  
662 the discrepancy to native tissue stiffness.<sup>1</sup> Despite having a higher elastic modulus in its dry state,  
663 PLGA undergoes bulk degradation through hydrolytic cleavage of ester bonds along the polymer  
664 backbone as water penetrates the matrix.<sup>73, 74</sup> As our work confirms, PLGA was previously shown  
665 to soften over the first 48 h due to a 221- 350% increase in water content.<sup>74, 75</sup> Previous work with  
666 PLGA has demonstrated a significant reduction of the elastic modulus due to matrix swelling and  
667 rapid loss of molecular weight through the bulk degradation process.<sup>73, 75</sup> In our study, hydration  
668 of PLGA microspheres reduced the elastic modulus by approximately four-fold. The microspheres  
669 used here were designed to be a malleable substrate that softens and degrades, allowing for cell  
670 remodeling and migration.<sup>16</sup>

671

672 The undefined ECM and growth factor milieu of naturally-derived hydrogels exposes self-  
673 aggregating and self-organizing cells to a poorly controlled mix of excitatory, proliferative,  
674 instructive, mechanotransducive, and inhibitory signals.<sup>16, 51, 76</sup> Matrigel-based methods can result  
675 in low reproducibility and poor control of differentiation due to the inherent variability within  
676 Matrigel.<sup>4, 77</sup> The use of a chemically undefined environments may also obscure or limit the utility  
677 of observations.<sup>4, 16, 18, 72, 78, 79</sup> The use of serum-free formulations has created more defined and  
678 consistent neural differentiation methods.<sup>10, 80, 81</sup> Therefore, a more defined 3D structure which  
679 incorporates neural ECM components would be a beneficial differentiation platform. Through  
680 incorporation of substrate-specific matrices such as PLO+laminin, this study offers improved  
681 control over the *in vitro* microenvironment by providing physiologically relevant cues found in the  
682 brain.<sup>1, 10, 66, 76, 82, 83</sup> We have demonstrated microspheres promote iPSC-derived NSC growth and  
683 differentiation. Compared to cell-only 3D neurospheres, which rely on cell aggregation, cell-  
684 secreted ECM proteins, and self-organization to generate the 3D structure, the microspheres can  
685 be coated with ECM proteins and ligands to mechanically and chemically direct stem cell  
686 differentiation. Scaffolds with high porosity and nearly 100% interconnected pore structure, such  
687 as the microsphere platform presented here, allow for nutrients, oxygen, and waste products to  
688 be transported throughout the biomaterial-based organoid structure.<sup>1, 84</sup> We have modeled the  
689 flow of solution through the microsphere by the deposition of HA crystals throughout the internal  
690 architecture of the microsphere. The larger surface area, porosity, and biocompatibility of PLGA  
691 microspheres support cell attachment, growth and differentiation.<sup>4, 32, 85</sup> The acidic by-products  
692 that form upon matrix degradation can lower the pH and lead to inflammation within PLGA-based  
693 scaffolds.<sup>74, 86, 87</sup> However, less than 12% of our microsphere volume is composed of PLGA.  
694 Further, the interconnected pore structure allows lactic acid and glycolic acid monomers to be  
695 diluted within the surrounding media, limiting toxicity on scaffold-based cells.<sup>64, 66, 87</sup> Lastly, the  
696 porous matrix and the high surface area of the scaffolds create a supportive environment that  
697 promote cellular health and complexity compared to cell-based neurospheres.  
698

699 Due to the frequent inability of animal models to recapitulate disease manifestation,<sup>1, 14, 88</sup> the  
700 ability to model human disease using iPSCs in a 3D environment is critical for both basic and  
701 translational research. The ability to model human disease *in vitro* with iPSCs allows access to  
702 both unaffected and disease-impacted cell types of interest, providing opportunities for analysis  
703 of disease pathogenesis or drug discovery studies.<sup>2</sup> However, the cellular complexity of iPSC-  
704 based neurological models has been limited due to the stochastic nature of the differentiation  
705 process. We have demonstrated that our 3D microsphere-based scaffold system can function as

706 an *in vitro* neurodevelopment platform using iPSC-derived cells. Our system can support both  
707 unaffected and disease-affected iPSC models, as well as combinatorial culture of progenitors,  
708 differentiated neuronal and glial cell types, and endothelium.<sup>1, 6, 27, 50, 88 41</sup>

709  
710 While we have demonstrated our microsphere platform can successfully host cell types of interest,  
711 future studies utilizing this platform will determine the functional activity of cultured cells, the  
712 impact of cell-to-cell interactions, optimization of cell populations, and utilization of ECM coatings  
713 favorable to specific cell types. Such studies will involve prolonged, multi-month culture to allow  
714 maturation and functional development of cellular networks as has previously been performed in  
715 self-organizing cerebral organoid models.<sup>17, 89</sup> Through directed differentiation towards specific  
716 cell types of interest on separate scaffolds, the microspheres could be combined, similar to  
717 assembloids, to create composite scaffolds with greater heterogeneity and functionality.<sup>90, 91</sup> The  
718 microsphere-based scaffold architecture offers a unique platform to assemble distinct clusters of  
719 differentiating cells to maximize recapitulation of CNS regions of interest. Future studies will  
720 therefore be needed to determine the precise impact of our microsphere scaffold on the formation  
721 and function of defined neuronal and glial populations.

722  
723 Our data demonstrates the microsphere platform described can function as both a cellular scaffold  
724 and growth factor elution system consisting of biocompatible materials. This work provides  
725 important proof-of-concept data regarding the multifunctionality of this system. The HA coated  
726 microspheres described here can be loaded with multiple growth factors, as demonstrated by  
727 incorporation of two fluorescently bound molecules. Future work will evaluate other bioactive  
728 molecules, such as silk nanofibers, which limit substrate stiffness compared to HA for the  
729 incorporation and release of soluble factors.<sup>92</sup> The incorporation of physiologically critical growth  
730 factors, such as bFGF, into a 3D platform has the capacity to promote progenitor proliferation or  
731 drive cellular differentiation without additional environmental manipulation. Proteins, peptides and  
732 other small molecules can thus be released directly to cells to modify a signaling pathway or  
733 cellular function without disturbing the growing organoid. The porous structure allows for a much  
734 greater loading capacity due to the surface area, as well as the rapid clearance of any acidic by-  
735 products that may interfere with the bioactivity of sensitive molecules.<sup>74</sup> We demonstrated that  
736 bFGF, released from microspheres over 14 days, increased proliferation above the level of the  
737 2D monolayer which was receiving bFGF supplemented media every other day. In a similar  
738 manner to coating microspheres with various proteins to model different ECM substrates, the  
739 microspheres can be dual loaded with factors to influence attached cells. For example, the

740 addition of a bioceramic component to PLGA microspheres is applicable for use in other, non-  
741 neural tissue engineering models.

742 In summary, we have developed a chemically-defined, microsphere-based cell culture platform  
743 to model neurodevelopment and disease pathogenesis using iPSC derivatives. The microspheres  
744 developed in this study represent a biodegradable, highly porous, customizable substrate capable  
745 of hosting NSCs and differentiated cells types for weeks *in vitro*. We show that the platform can  
746 be customized with various extracellular matrices such as PLO and laminin to support proliferation  
747 or directed differentiation, as desired. We further demonstrate these microspheres can support  
748 multiple neural and non-neural cell types simultaneously, through co-culture of NSCs, NSC-  
749 differentiated neurons, mature astrocytes, and HUVEC cells. Lastly, modified microspheres can  
750 simultaneously function as both a cellular scaffold and small molecule delivery platform. Future  
751 work will utilize the biophysical and nanoarchitectonic cues utilized here to generate complex  
752 culture systems for the study of development, disease pathogenesis, or 3D-based drug discovery  
753 assays.

754

## 755 **Acknowledgements**

756 We would like to thank the University of South Dakota Center for Brain and Behavior Research  
757 and the University of South Dakota Neuroscience, Nanotechnology, and Networks programs for  
758 their support. We would like to thank Kelly Graber and Claire Evans for assistance with H&E  
759 immunohistochemistry. The graphical abstract was created using BioRender.com.

## 760 **Author contributions**

761 ES, HS, and KRF conceived the study. ES performed most of the experiments under the  
762 supervision of DE and KRF. SVJ performed analysis of scaffold mechanical properties under the  
763 supervision of DRK and KSK. ES and KRF wrote the manuscript. All authors discussed the results  
764 and approved the final manuscript.

## 765 **Declaration of conflicting interests**

766 The authors declare no potential conflicts of interest with respect to the research, authorship,  
767 and/or publication of this article.

768 **Funding**

769 This study was supported by NIH grants (NIGMS P20 GM103620 and P20 GM103548), the  
770 National Science Foundation (DGE-1633213), a National Science Foundation/EPSCoR  
771 Cooperative Agreement (IIA-1355423), a National Science Foundation/EPSCoR Cooperative  
772 Agreement (OIA-1946202), and the State of South Dakota. The content is solely the responsibility  
773 of the authors and does not necessarily represent the official views of the National Institutes of  
774 Health or the National Science Foundation.

775 **ORCID iD for corresponding author**

776 Kevin Francis, <https://orcid.org/0000-0002-3636-7264>

777 **Statement of significance**

778 In this study, highly porous PLGA microspheres were prepared using a double emulsion and  
779 porogen leaching technique. The resulting microspheres were used as a 3D platform to culture  
780 control and patient iPSC-derived neural stem cells as a model for neurodevelopment. The goal of  
781 this research was to demonstrate that protein-coated microspheres could serve as a suitable *in*  
782 *vitro* model for the developing brain. Through our *in vitro* biological results, we have shown that  
783 the porous PLGA microspheres developed herein can simultaneously support multilineage  
784 differentiation, co-culture of neural and non-neural lineages, and directly deliver small molecules  
785 to 3D neural models. This platform represents a significant step in creating more reproducible  
786 three-dimensional models for the *in vitro* study of human disease or for use in drug discovery  
787 assays.

788 **Data availability statement**

789 Datasets generated in this study are available from the corresponding author upon request.

790 **References**

- 791 1. Murphy AR, Laslett A, O'Brien CM, et al. Scaffolds for 3D *in vitro* culture of neural lineage cells.  
792 *Acta Biomater* 2017; 54: 1-20. 2017/03/06. DOI: 10.1016/j.actbio.2017.02.046.
- 793 2. Sloan SA, Andersen J, Pasca AM, et al. Generation and assembly of human brain region-specific  
794 three-dimensional cultures. *Nat Protoc* 2018; 13: 2062-2085. 2018/09/12. DOI: 10.1038/s41596-018-  
795 0032-7.
- 796 3. Chukwurah E, Osmundsen A, Davis SW, et al. All Together Now: Modeling the Interaction of  
797 Neural With Non-neural Systems Using Organoid Models. *Front Neurosci* 2019; 13: 582. 2019/07/12.  
798 DOI: 10.3389/fnins.2019.00582.
- 799 4. Poli D, Magliaro C and Ahluwalia A. Experimental and Computational Methods for the Study of  
800 Cerebral Organoids: A Review. *Front Neurosci* 2019; 13: 162. 2019/03/21. DOI:  
801 10.3389/fnins.2019.00162.

802 5. Centeno EGZ, Cimarosti H and Bithell A. 2D versus 3D human induced pluripotent stem cell-  
803 derived cultures for neurodegenerative disease modelling. *Mol Neurodegener* 2018; 13: 27. 2018/05/24.  
804 DOI: 10.1186/s13024-018-0258-4.

805 6. Lage OM, Ramos MC, Calisto R, et al. Current Screening Methodologies in Drug Discovery for  
806 Selected Human Diseases. *Mar Drugs* 2018; 16 2018/08/17. DOI: 10.3390/md16080279.

807 7. Saxe JP, Wu H, Kelly TK, et al. A phenotypic small-molecule screen identifies an orphan ligand-  
808 receptor pair that regulates neural stem cell differentiation. *Chem Biol* 2007; 14: 1019-1030.  
809 2007/09/22. DOI: 10.1016/j.chembiol.2007.07.016.

810 8. Zhao WN, Cheng C, Theriault KM, et al. A high-throughput screen for Wnt/β-catenin signaling  
811 pathway modulators in human iPSC-derived neural progenitors. *J Biomol Screen* 2012; 17: 1252-1263.  
812 2012/08/28. DOI: 10.1177/1087057112456876.

813 9. Horvath P, Aulner N, Bickle M, et al. Screening out irrelevant cell-based models of disease. *Nat  
814 Rev Drug Discov* 2016; 15: 751-769. 2016/11/04. DOI: 10.1038/nrd.2016.175.

815 10. Chen AK, Reuveny S and Oh SK. Application of human mesenchymal and pluripotent stem cell  
816 microcarrier cultures in cellular therapy: achievements and future direction. *Biotechnol Adv* 2013; 31:  
817 1032-1046. 2013/03/28. DOI: 10.1016/j.biotechadv.2013.03.006.

818 11. Shah SB and Singh A. Cellular self-assembly and biomaterials-based organoid models of  
819 development and diseases. *Acta Biomater* 2017; 53: 29-45. 2017/02/06. DOI:  
820 10.1016/j.actbio.2017.01.075.

821 12. Koo B, Choi B, Park H, et al. Past, Present, and Future of Brain Organoid Technology. *Mol Cells*  
822 2019; 42: 617-627. 2019/09/30. DOI: 10.14348/molcells.2019.0162.

823 13. Edmondson R, Broglie JJ, Adcock AF, et al. Three-dimensional cell culture systems and their  
824 applications in drug discovery and cell-based biosensors. *Assay Drug Dev Technol* 2014; 12: 207-218.  
825 2014/05/17. DOI: 10.1089/adt.2014.573.

826 14. Wang H. Modeling Neurological Diseases With Human Brain Organoids. *Front Synaptic Neurosci*  
827 2018; 10: 15. 2018/06/26. DOI: 10.3389/fnsyn.2018.00015.

828 15. Amin ND and Pasca SP. Building Models of Brain Disorders with Three-Dimensional Organoids.  
829 *Neuron* 2018; 100: 389-405. 2018/10/26. DOI: 10.1016/j.neuron.2018.10.007.

830 16. Yin X, Mead BE, Safaee H, et al. Engineering Stem Cell Organoids. *Cell Stem Cell* 2016; 18: 25-38.  
831 2016/01/11. DOI: 10.1016/j.stem.2015.12.005.

832 17. Lancaster MA and Knoblich JA. Generation of cerebral organoids from human pluripotent stem  
833 cells. *Nat Protoc* 2014; 9: 2329-2340. DOI: 10.1038/nprot.2014.158.

834 18. Lee CT, Bendriem RM, Wu WW, et al. 3D brain Organoids derived from pluripotent stem cells:  
835 promising experimental models for brain development and neurodegenerative disorders. *J Biomed Sci*  
836 2017; 24: 59. 2017/08/22. DOI: 10.1186/s12929-017-0362-8.

837 19. Logan S, Arzua T, Canfield SG, et al. Studying Human Neurological Disorders Using Induced  
838 Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. *Compr  
839 Physiol* 2019; 9: 565-611. 2019/03/16. DOI: 10.1002/cphy.c180025.

840 20. Kim SJ, Kim EM, Yamamoto M, et al. Engineering Multi-Cellular Spheroids for Tissue Engineering  
841 and Regenerative Medicine. *Adv Healthc Mater* 2020: e2000608. 2020/08/01. DOI:  
842 10.1002/adhm.202000608.

843 21. Heo DN, Hospoduk M and Ozbolat IT. Synergistic interplay between human MSCs and HUVECs  
844 in 3D spheroids laden in collagen/fibrin hydrogels for bone tissue engineering. *Acta Biomater* 2019; 95:  
845 348-356. 2019/03/05. DOI: 10.1016/j.actbio.2019.02.046.

846 22. Yang Y, Bajaj N, Xu P, et al. Development of highly porous large PLGA microparticles for  
847 pulmonary drug delivery. *Biomaterials* 2009; 30: 1947-1953. 2009/01/13. DOI:  
848 10.1016/j.biomaterials.2008.12.044.

849 23. Galiakberova AA and Dashinimaev EB. Neural Stem Cells and Methods for Their Generation  
850 From Induced Pluripotent Stem Cells in vitro. *Front Cell Dev Biol* 2020; 8: 815. 2020/10/30. DOI:  
851 10.3389/fcell.2020.00815.

852 24. Gjorevski N, Ranga A and Lutolf MP. Bioengineering approaches to guide stem cell-based  
853 organogenesis. *Development* 2014; 141: 1794-1804. 2014/04/24. DOI: 10.1242/dev.101048.

854 25. Huch M, Knoblich JA, Lutolf MP, et al. The hope and the hype of organoid research.  
855 *Development* 2017; 144: 938-941. 2017/03/16. DOI: 10.1242/dev.150201.

856 26. Jensen G, Morrill C and Huang Y. 3D tissue engineering, an emerging technique for  
857 pharmaceutical research. *Acta Pharm Sin B* 2018; 8: 756-766. 2018/09/28. DOI:  
858 10.1016/j.apsb.2018.03.006.

859 27. Lancaster MA and Knoblich JA. Organogenesis in a dish: modeling development and disease  
860 using organoid technologies. *Science* 2014; 345: 1247125. DOI: 10.1126/science.1247125.

861 28. Yu X, Dillon GP and Bellamkonda RB. A laminin and nerve growth factor-laden three-dimensional  
862 scaffold for enhanced neurite extension. *Tissue Eng* 1999; 5: 291-304. 1999/09/09. DOI:  
863 10.1089/ten.1999.5.291.

864 29. Horch RE, Weigand A, Wajant H, et al. [Biofabrication: new approaches for tissue regeneration].  
865 *Handchir Mikrochir Plast Chir* 2018; 50: 93-100. 2018/01/30. DOI: 10.1055/s-0043-124674.

866 30. Ariga K. Progress in Molecular Nanoarchitectonics and Materials Nanoarchitectonics. *Molecules*  
867 2021; 26 2021/04/04. DOI: 10.3390/molecules26061621.

868 31. Ariga K. Nanoarchitectonics: what's coming next after nanotechnology? *Nanoscale Horiz* 2021;  
869 6: 364-378. 2021/05/06. DOI: 10.1039/d0nh00680g.

870 32. Qutachi O, Vetsch JR, Gill D, et al. Injectable and porous PLGA microspheres that form highly  
871 porous scaffolds at body temperature. *Acta Biomater* 2014; 10: 5090-5098. 2014/08/26. DOI:  
872 10.1016/j.actbio.2014.08.015.

873 33. Kokubo T and Takadama H. How useful is SBF in predicting in vivo bone bioactivity? *Biomaterials*  
874 2006; 27: 2907-2915. 2006/02/02. DOI: 10.1016/j.biomaterials.2006.01.017.

875 34. Yao Q, Sandhurst ES, Liu Y, et al. BBP-Functionalized Biomimetic Nanofibrous Scaffold Can  
876 Capture BMP2 and Promote Osteogenic Differentiation. *J Mater Chem B* 2017; 5: 5196-5205.  
877 2017/12/19. DOI: 10.1039/C7TB00744B.

878 35. Cheng MT, Yang HW, Chen TH, et al. Modulation of proliferation and differentiation of human  
879 anterior cruciate ligament-derived stem cells by different growth factors. *Tissue Eng Part A* 2009; 15:  
880 3979-3989. 2009/07/10. DOI: 10.1089/ten.TEA.2009.0172.

881 36. Grazul-Bilska AT, Johnson ML, Bilska JJ, et al. Wound healing: the role of growth factors. *Drugs*  
882 Today (Barc) 2003; 39: 787-800. 2003/12/12. DOI: 10.1358/dot.2003.39.10.799472.

883 37. W.C. Oliver GMP. Measurement of hardness and elastic modulus by instrumented indentation:  
884 Advances in understanding and refinements to methodology. *Journal of Materials Research* 2004; 19: 3-  
885 20. Review.

886 38. W.C. Oliver GMP. An Improved Technique for Determining Hardness and Elastic Modulus Using  
887 Load Displacement Sensing Indentation Experiments. *Journal of Materials Research* 1992; 7: 1564-1583.  
888 DOI: <https://doi.org/10.1557/JMR.1992.1564>.

889 39. Kar S, Katti DR and Katti KS. Evaluation of quasi-static and dynamic nanomechanical properties  
890 of bone-metastatic breast cancer cells using a nanoclay cancer testbed. *Sci Rep* 2021; 11: 3096.  
891 2021/02/06. DOI: 10.1038/s41598-021-82664-9.

892 40. Molla MS, Katti DR and Katti KS. Mechanobiological evaluation of prostate cancer metastasis to  
893 bone using an in vitro prostate cancer testbed. *J Biomech* 2021; 114: 110142. 2020/12/09. DOI:  
894 10.1016/j.jbiomech.2020.110142.

41. Francis KR, Ton AN, Xin Y, et al. Modeling Smith-Lemli-Opitz syndrome with induced pluripotent stem cells reveals a causal role for Wnt/beta-catenin defects in neuronal cholesterol synthesis phenotypes. *Nat Med* 2016; 22: 388-396. 2016/03/22. DOI: 10.1038/nm.4067.

42. Malik N, Wang X, Shah S, et al. Comparison of the gene expression profiles of human fetal cortical astrocytes with pluripotent stem cell derived neural stem cells identifies human astrocyte markers and signaling pathways and transcription factors active in human astrocytes. *PLoS One* 2014; 9: e96139. DOI: 10.1371/journal.pone.0096139.

43. Hung CH and Young TH. Differences in the effect on neural stem cells of fetal bovine serum in substrate-coated and soluble form. *Biomaterials* 2006; 27: 5901-5908. 2006/09/02. DOI: 10.1016/j.biomaterials.2006.08.009.

44. Sawyer AA, Hennessy KM and Bellis SL. Regulation of mesenchymal stem cell attachment and spreading on hydroxyapatite by RGD peptides and adsorbed serum proteins. *Biomaterials* 2005; 26: 1467-1475. 2004/11/04. DOI: 10.1016/j.biomaterials.2004.05.008.

45. Fang CY, Wu CC, Fang CL, et al. Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines. *PLoS One* 2017; 12: e0178960. 2017/06/08. DOI: 10.1371/journal.pone.0178960.

46. Hemeda H, Giebel B and Wagner W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. *Cytotherapy* 2014; 16: 170-180. 2014/01/21. DOI: 10.1016/j.jcyt.2013.11.004.

47. Hu BY and Zhang SC. Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. *Methods Mol Biol* 2010; 636: 123-137. 2010/03/26. DOI: 10.1007/978-1-60761-691-7\_8.

48. Schulz TC, Noggle SA, Palmarini GM, et al. Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. *Stem Cells* 2004; 22: 1218-1238. 2004/12/08. DOI: 10.1634/stemcells.2004-0114.

49. Chuang JH, Tung LC and Lin Y. Neural differentiation from embryonic stem cells in vitro: An overview of the signaling pathways. *World J Stem Cells* 2015; 7: 437-447. 2015/03/31. DOI: 10.4252/wjsc.v7.i2.437.

50. Fang Y and Eglen RM. Three-Dimensional Cell Cultures in Drug Discovery and Development. *SLAS DISCOVERY: Advancing Life Sciences R&D* 2017. DOI: 10.1177/2472555217696795.

51. Hughes CS, Postovit LM and Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. *Proteomics* 2010; 10: 1886-1890. 2010/02/18. DOI: 10.1002/pmic.200900758.

52. Scholzen T and Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000; 182: 311-322. 2000/02/01. DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.

53. Melissaridou S, Wiechec E, Magan M, et al. The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in head and neck cancer. *Cancer Cell Int* 2019; 19: 16. 2019/01/18. DOI: 10.1186/s12935-019-0733-1.

54. Li X, Chu J, Wang A, et al. Uniaxial mechanical strain modulates the differentiation of neural crest stem cells into smooth muscle lineage on micropatterned surfaces. *PLoS One* 2011; 6: e26029. 2011/10/22. DOI: 10.1371/journal.pone.0026029.

55. Porter FD and Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. *J Lipid Res* 2011; 52: 6-34. Research Support, N.I.H., Extramural

56. Pham MT, Pollock KM, Rose MD, et al. Generation of human vascularized brain organoids. *Neuroreport* 2018; 29: 588-593. 2018/03/24. DOI: 10.1097/WNR.0000000000001014.

941 57. Shafiee S, Shariatzadeh S, Zafari A, et al. Recent Advances on Cell-Based Co-Culture Strategies  
942 for Prevascularization in Tissue Engineering. *Front Bioeng Biotechnol* 2021; 9: 745314. 2021/12/14. DOI:  
943 10.3389/fbioe.2021.745314.

944 58. Risau W and Flamme I. Vasculogenesis. *Annu Rev Cell Dev Biol* 1995; 11: 73-91. 1995/01/01.  
945 DOI: 10.1146/annurev.cb.11.110195.000445.

946 59. Santos C, Gomes P, Duarte JA, et al. Development of hydroxyapatite nanoparticles loaded with  
947 folic acid to induce osteoblastic differentiation. *Int J Pharm* 2017; 516: 185-195. 2016/11/17. DOI:  
948 10.1016/j.ijpharm.2016.11.035.

949 60. Bodhak S, de Castro LF, Kuznetsov SA, et al. Combinatorial cassettes to systematically evaluate  
950 tissue-engineered constructs in recipient mice. *Biomaterials* 2018; 186: 31-43. 2018/10/03. DOI:  
951 10.1016/j.biomaterials.2018.09.035.

952 61. Kuznetsov SA, Cherman N and Robey PG. In vivo bone formation by progeny of human  
953 embryonic stem cells. *Stem Cells Dev* 2011; 20: 269-287. 2010/07/02. DOI: 10.1089/scd.2009.0501.

954 62. Hao M, Zhang Z, Liu C, et al. Hydroxyapatite Nanorods Function as Safe and Effective Growth  
955 Factors Regulating Neural Differentiation and Neuron Development. *Adv Mater* 2021; 33: e2100895.  
956 2021/07/12. DOI: 10.1002/adma.202100895.

957 63. Shen Y, Liu F, Duan J, et al. Biomaterial Cues Regulated Differentiation of Neural Stem Cells into  
958 GABAergic Neurons through Ca(2+)/c-Jun/TLX3 Signaling Promoted by Hydroxyapatite Nanorods. *Nano*  
959 *Lett* 2021; 21: 7371-7378. 2021/08/24. DOI: 10.1021/acs.nanolett.1c02708.

960 64. Loh QL and Choong C. Three-dimensional scaffolds for tissue engineering applications: role of  
961 porosity and pore size. *Tissue Eng Part B Rev* 2013; 19: 485-502. 2013/05/16. DOI:  
962 10.1089/ten.TEB.2012.0437.

963 65. Makadia HK and Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug  
964 Delivery Carrier. *Polymers (Basel)* 2011; 3: 1377-1397. 2012/05/12. DOI: 10.3390/polym3031377.

965 66. Krishna L, Dhamodaran K, Jayadev C, et al. Nanostructured scaffold as a determinant of stem cell  
966 fate. *Stem Cell Res Ther* 2016; 7: 188. 2017/01/01. DOI: 10.1186/s13287-016-0440-y.

967 67. Kim SH, Kim JE, Kim SH, et al. Substance P/dexamethasone-encapsulated PLGA scaffold  
968 fabricated using supercritical fluid process for calvarial bone regeneration. *J Tissue Eng Regen Med* 2017;  
969 11: 3469-3480. 2017/06/02. DOI: 10.1002/term.2260.

970 68. Raeisdasteh Hokmabad V, Davaran S, Ramazani A, et al. Design and fabrication of porous  
971 biodegradable scaffolds: a strategy for tissue engineering. *J Biomater Sci Polym Ed* 2017; 28: 1797-1825.  
972 2017/07/15. DOI: 10.1080/09205063.2017.1354674.

973 69. Davies JE, Matta R, Mendes VC, et al. Development, characterization and clinical use of a  
974 biodegradable composite scaffold for bone engineering in oro-maxillo-facial surgery. *Organogenesis*  
975 2010; 6: 161-166. 2011/01/05. DOI: 10.4161/org.6.3.12392.

976 70. Papadimitriou L, Manganas P, Ranella A, et al. Biofabrication for neural tissue engineering  
977 applications. *Mater Today Bio* 2020; 6: 100043. 2020/03/20. DOI: 10.1016/j.mtbio.2020.100043.

978 71. Yamagata K, Nakayamada S and Tanaka Y. Use of mesenchymal stem cells seeded on the  
979 scaffold in articular cartilage repair. *Inflamm Regen* 2018; 38: 4. 2018/03/22. DOI: 10.1186/s41232-018-  
980 0061-1.

981 72. Zhuang P, Sun AX, An J, et al. 3D neural tissue models: From spheroids to bioprinting.  
982 *Biomaterials* 2018; 154: 113-133. 2017/11/10. DOI: 10.1016/j.biomaterials.2017.10.002.

983 73. Clark A, Milbrandt TA, Hilt JZ, et al. Tailoring properties of microsphere-based poly(lactic-co-  
984 glycolic acid) scaffolds. *J Biomed Mater Res A* 2014; 102: 348-357. 2013/03/28. DOI:  
985 10.1002/jbm.a.34706.

986 74. Keles H, Naylor A, Clegg F, et al. Investigation of factors influencing the hydrolytic degradation of  
987 single PLGA microparticles. *Polymer Degradation and Stability* 2015; 119: 228-241. DOI:  
988 10.1016/j.polymdegradstab.2015.04.025.

989 75. Kranz H, Ubrich N, Maincent P, et al. Physicomechanical properties of biodegradable poly(D,L-  
990 lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. *J Pharm Sci* 2000; 89: 1558-  
991 1566. 2000/10/24. DOI: 10.1002/1520-6017(200012)89:12<1558::aid-jps6>3.0.co;2-8.

992 76. Hazeltine LB, Selekman JA and Palecek SP. Engineering the human pluripotent stem cell  
993 microenvironment to direct cell fate. *Biotechnol Adv* 2013; 31: 1002-1019. 2013/03/21. DOI:  
994 10.1016/j.biotechadv.2013.03.002.

995 77. Yakoub AM and Sadek M. Development and Characterization of Human Cerebral Organoids: An  
996 Optimized Protocol. *Cell Transplant* 2018; 27: 393-406. 2018/05/12. DOI: 10.1177/0963689717752946.

997 78. Langhans SA. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug  
998 Repositioning. *Front Pharmacol* 2018; 9: 6. 2018/02/08. DOI: 10.3389/fphar.2018.00006.

999 79. Marti-Figueroa CR and Ashton RS. The case for applying tissue engineering methodologies to  
1000 instruct human organoid morphogenesis. *Acta Biomater* 2017; 54: 35-44. 2017/03/21. DOI:  
1001 10.1016/j.actbio.2017.03.023.

1002 80. Vieira MS, Santos AK, Vasconcellos R, et al. Neural stem cell differentiation into mature neurons:  
1003 Mechanisms of regulation and biotechnological applications. *Biotechnol Adv* 2018; 36: 1946-1970.  
1004 2018/08/06. DOI: 10.1016/j.biotechadv.2018.08.002.

1005 81. Verma I, Rashid Z, Sikdar SK, et al. Efficient neural differentiation of mouse pluripotent stem  
1006 cells in a serum-free medium and development of a novel strategy for enrichment of neural cells. *Int J  
1007 Dev Neurosci* 2017; 61: 112-124. 2017/07/05. DOI: 10.1016/j.ijdevneu.2017.06.009.

1008 82. Hellwig C, Barenys M, Baumann J, et al. Culture of human neurospheres in 3D scaffolds for  
1009 developmental neurotoxicity testing. *Toxicol In Vitro* 2018; 52: 106-115. 2018/06/09. DOI:  
1010 10.1016/j.tiv.2018.06.002.

1011 83. Koh HS, Yong T, Chan CK, et al. Enhancement of neurite outgrowth using nano-structured  
1012 scaffolds coupled with laminin. *Biomaterials* 2008; 29: 3574-3582. 2008/06/06. DOI:  
1013 10.1016/j.biomaterials.2008.05.014.

1014 84. Chou MJ, Hsieh CH, Yeh PL, et al. Application of open porous poly(D,L-lactide-co-glycolide)  
1015 microspheres and the strategy of hydrophobic seeding in hepatic tissue cultivation. *J Biomed Mater Res  
1016 A* 2013; 101: 2862-2869. 2013/03/19. DOI: 10.1002/jbm.a.34594.

1017 85. Kang SW and Bae YH. Cryopreservable and tumorigenic three-dimensional tumor culture in  
1018 porous poly(lactic-co-glycolic acid) microsphere. *Biomaterials* 2009; 30: 4227-4232. 2009/05/19. DOI:  
1019 10.1016/j.biomaterials.2009.04.025.

1020 86. Jakobsson A, Ottosson M, Zalis MC, et al. Three-dimensional functional human neuronal  
1021 networks in uncompressed low-density electrospun fiber scaffolds. *Nanomedicine* 2017; 13: 1563-1573.  
1022 2017/01/09. DOI: 10.1016/j.nano.2016.12.023.

1023 87. Sensharma P, Madhumathi G, Jayant RD, et al. Biomaterials and cells for neural tissue  
1024 engineering: Current choices. *Mater Sci Eng C Mater Biol Appl* 2017; 77: 1302-1315. 2017/05/24. DOI:  
1025 10.1016/j.msec.2017.03.264.

1026 88. Hofrichter M, Nimtz L, Tigges J, et al. Comparative performance analysis of human iPSC-derived  
1027 and primary neural progenitor cells (NPC) grown as neurospheres in vitro. *Stem Cell Res* 2017; 25: 72-82.  
1028 2017/11/08. DOI: 10.1016/j.scr.2017.10.013.

1029 89. Martens YA, Xu S, Tait R, et al. Generation and validation of APOE knockout human iPSC-derived  
1030 cerebral organoids. *STAR Protoc* 2021; 2: 100571. 2021/06/22. DOI: 10.1016/j.xpro.2021.100571.

1031 90. Pasca SP. Assembling human brain organoids. *Science* 2019; 363: 126-127. 2019/01/12. DOI:  
1032 10.1126/science.aaau5729.

1033 91. Marton RM and Pasca SP. Organoid and Assembloid Technologies for Investigating Cellular  
1034 Crosstalk in Human Brain Development and Disease. *Trends Cell Biol* 2019; 29: 126-127. 2019/12/28. DOI:  
1035 10.1016/j.tcb.2019.11.004.

1036 92. Wang X, Wenk E, Zhang X, et al. Growth factor gradients via microsphere delivery in biopolymer  
1037 scaffolds for osteochondral tissue engineering. *J Control Release* 2009; 134: 81-90. 2008/12/17. DOI:  
1038 10.1016/j.jconrel.2008.10.021.

1039